Navigation Links
BioLife Solutions Joins Prestigious Biomedical Excellence for Safer Transfusion Collaborative
Date:12/29/2008

BOTHELL, Wash., Dec. 29 /PRNewswire-FirstCall/ -- BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading developer and marketer of proprietary cGMP hypothermic storage and cryopreservation media products for cells, tissues, and organs, today announced that it has joined the Biomedical Excellence for Safer Transfusion (BEST) Collaborative, an international consortium of leading scientific, clinical, and commercial partners whose mission is to explore collaborative ways to improve transfusion-related services through standardization of analytic techniques, development of new procedures and execution of clinical trials in hemotherapy.

Zbigniew "Ziggy" M. Szczepiorkowski, MD, PhD, co-chair of the BEST cellular therapy team and Associate Professor of Pathology and of Medicine at Dartmouth Medical School, commented on the addition of BioLife Solutions as a new corporate member of BEST by stating, "We're very pleased to welcome BioLife to the BEST Collaborative. BioLife joins other corporate members in the quest to advance the field of transfusion medicine and to work with world leading experts. Results from recent initial safety studies conducted by BioLife and submission of FDA Master Files understandably elevates the profile of the company in the field of transfusion medicine in the US and internationally. We look forward to mutually beneficial scientific collaboration with BioLife and other BEST corporate members to identify ways to extend the shelf-life and improve the transportation logistics as well as post-preservation viability and functional yield of transfusion-related source material and derived cell-based clinical products."

Mike Rice, BioLife's chairman and CEO, noted "Since its formation, the scientific members of BEST have collectively published over 50 peer reviewed scientific articles related to efforts to continually improve quality, safety and efficiency in transfusion medicine. W
'/>"/>

SOURCE BioLife Solutions, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM)
2. BioLife Solutions Granted European Biopreservation Patent
3. BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues
4. BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes
5. BioLife Solutions Credit Facility Increased to $9 Million
6. BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media
7. BioLife Solutions Outsourcing Manufacturing, Warehousing, and Order Fulfillment to Bioserv Corporation
8. BioLife Solutions CryoStor(TM) Adopted by Tissue Regeneration Therapeutics for Preservation Protocol for New, Non-Embryonic Source of Stem Cells
9. BioLife Solutions Expands Scientific Advisory Board
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. DuPont Acquires Ag Data Management Business to Enhance Information Solutions for Growers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... July 28, 2015 , ... In terms of value, aluminium ... production volume reached close to 1.84 million tonnes in the same year. As ... of the region’s total aluminium hydroxide production; the country’s aluminium hydroxide production posted ...
(Date:7/28/2015)... , ... July 28, 2015 , ... VetStem Biopharma will ... stem cell credentialing course to local area veterinarians. , The tour and course will ... units at no charge) at VetStem’s Poway facility. Staff members are welcome to attend ...
(Date:7/28/2015)...  Kerastem Technologies announce that the Company has received ... For Biologics Evaluation and Research (CBER) Office of Cellular, ... investigating the safety and feasibility of the Company,s technology ... baldness (androgenic alopecia). The phase II study, ... in Europe and ...
(Date:7/28/2015)... 2015 CSL Behring announced today ... for review the company,s Biologics License Application (BLA) for ... the treatment of hemophilia A. In the pivotal clinical ... Hemophilia A is a congenital bleeding disorder ... affected patients are male. People with hemophilia A may ...
Breaking Biology Technology:EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3
... HIFU Revenue ... FY2007 Annual Targets Under Review, BEIJING, ... (Nasdaq: CMED ), a leading China-based,medical device company ... and high intensity focused ultrasound tumor,therapy system, today announced ...
... LAKE CITY, Aug. 27 ARUP Laboratories, a ... leader in,innovative laboratory research and development, announced today ... with Premier Purchasing,Partners, L.P., one of the nation,s ... systems. The agreement extends a previous,contract between ARUP ...
... IDM Pharma (Nasdaq:,IDMI) today announced that Jeffrey W. ... Medical Officer and Senior Vice President,of Research and Development. ... report to President and CEO Timothy P. Walbert. ... experience to,IDM Pharma and will lead the regulatory and ...
Cached Biology Technology:China Medical Technologies Reports First Quarter Financial Results 2China Medical Technologies Reports First Quarter Financial Results 3China Medical Technologies Reports First Quarter Financial Results 4China Medical Technologies Reports First Quarter Financial Results 5China Medical Technologies Reports First Quarter Financial Results 6China Medical Technologies Reports First Quarter Financial Results 7China Medical Technologies Reports First Quarter Financial Results 8China Medical Technologies Reports First Quarter Financial Results 9China Medical Technologies Reports First Quarter Financial Results 10China Medical Technologies Reports First Quarter Financial Results 11China Medical Technologies Reports First Quarter Financial Results 12China Medical Technologies Reports First Quarter Financial Results 13China Medical Technologies Reports First Quarter Financial Results 14ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services 2IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 2IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 3IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 4IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 5
(Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
(Date:6/24/2015)... June 24, 2015 This report provides market ... next six years. It contains an analysis of the ... with their impact from the short, medium, and long ... the industry, market, and technology trends that currently, prevail ... of concerned authorities to efficiently manage the increasing marine ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... have found that a type of amoeba acts as ... found in healthcare environments this discovery has implications for ... single cell amoeba, Acanthamoeba polyphagam commonly eats and digests ... However, instead of being digested by the amoeba, MRSA ...
... (HSP) can be utilized as a vaccine to ... National University (South Korea) today presented the findings ... bacterium Porphyromonas gingivalis heat-shock protein (HSP) 60 as ... bone loss.Recombinant P. gingivalis HSP60 was produced and ...
... of Utah researchers have taken a potentially powerful new ... illnesses out of the test tube and into animals ... in mice. , The research has particularly important implications ... disease that damages both nerves and blood vessels. , ...
Cached Biology News:Proteins spur diabetic mice models to grow blood vessels, nerves 2
Vitellogenin (Japanese medaka) Standard...
nuclear RNA export factor 1, mRNA...
... of gene expression) technology allows ... profiles generated by SAGE are ... transcripts making it possible to ... Kit is designed to make ...
The Captivate Disposable Sample Chamber is designed for use with the Captivate magnetic yoke assembly (C-24700) and can be used with our Captivate ferrofluid conjugates (C-21473 C-21474 C-21476) or ...
Biology Products: